Activity of Trifluoperazine against Replicating, Non-Replicating and Drug Resistant M. tuberculosis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Advani, Meeta J ^a   Siddiqui, Imran ^b,c   Sharma, Pawan ^b,d   Reddy, Hemalatha ^a  

^a UNIVERSITY OF DELHI   (India)

^b International Centre of Genetic Engineering and Biotechnology   (India)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d North Eastern Region Biotechnology Programme Management Cell (NER BPMC)   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; PHENOTHIAZINE DERIVATIVE; TRIFLUOPERAZINE;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM ISOLATE; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; EX VIVO STUDY; IN VITRO STUDY; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PH; STARVATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CELL LINE; CELL SURVIVAL; DRUG RESISTANCE, BACTERIAL; HUMANS; HYDROGEN-ION CONCENTRATION; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE; TRIFLUOPERAZINE;

BACILLI (CLASS); CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 84865620422     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044245     Document Type: Article

References (40)

1. Haydel SE, (2010) Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery. Pharmaceutical 3: 2268-2290.
2. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K, (2011) The challenge of new drug discovery for tuberculosis. Nature 469: 483-490.
3. Vandonselaar M, Hickie RA, Quail JW, Delbaere LT, (1994) Trifluoperazine-induced conformational change in Ca2+-calmodulin. Nat Struct Biol 1: 795-801.
4. Amaral L, Martins M, Viveiros M, (2007) Phenothiazines as anti-multi-drug resistant tubercular agents. Infect Disord Drug Targets 7: 257-65.
5. Gadre DV, Talwar V, (1999) In vitro susceptibility testing of Mycobacterium tuberculosis strains to trifluoperazine. J Chemother 11: 203-6.
6. Gadre DV, Talwar V, Gupta HC, Murthy PS, (1998) Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis. Int Clin Psychopharmacol 13: 129-31.
7. Ratnakar P, Murthy PS, (1993) Trifluoperazine inhibits the incorporation of labelled precursors into lipids, proteins and DNA of Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett 110: 291-4.
8. Viveiros M, Leandro C, Amaral L, (2003) Mycobacterial efflux pumps and chemotherapeutic implications. Int J Antimicrob Agents 22: 274-8.
9. Kristiansen MM, Leandro C, Ordway D, Martins M, Viveiros M, et al. (2003) Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro. Int J Antimicrob Agents. 22: 250-3.
10. Kristiansen MM, Leandro C, Ordway D, Martins M, Viveiros M, et al. (2006) Thioridazine reduces resistance of methicillin-resistant staphylococcus aureus by inhibiting a reserpine-sensitive efflux pump. In Vivo 20: 361-6.
11. Kaatz GW, Moudgal VV, Seo SM, Kristiansen JE, (2003) Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother 47: 719-26.
12. Koul S, Somayajulu A, Advani MJ, Reddy H, (2009) A novel calcium binding protein in Mycobacterium tuberculosis-potential target for trifluoperazine. Indian J Exp Biol 47: 480-8.
13. Kumar D, Nath L, Kamal MA, Varshney A, Jain A, et al. (2010) Genome-wide Analysis of the Host Intracellular Network that Regulates Survival of Mycobacterium tuberculosis. Cell. 140: 731-43.
14. Ratnakar P, Murthy PS, (1992) Antitubercular activity of trifluoperazine, a calmodulin antagonist. FEMS Microbiol Lett 76: 73-6.
15. Luna-Herrera J, Reddy MV, Gangadharam PR, (1995) In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrob Agents Chemother 39: 440-4.
16. Rao SP, Ratnakar P, Murthy PS, Catanzaro A, (1995) Inhibitory and bactericidal activity of the calmodulin antagonist, trifluoperazine, against Mycobacterium avium in vitro and within human monocyte-derived macrophages. Indian J. Clin. Biochem. 10: 77-84.
17. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K, (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43: 717-31.
18. Theus SA, Cave MD, Eisenach KD, (2004) Activated THP-1 cells: an attractive model for the assessment of intracellular growth rates of Mycobacterium tuberculosis isolates. Infect Immun 72: 1169-73.
19. Amaral L, Kristiansen JE, Viveiros M, Atouguia J, (2001) Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J Antimicrob Chemother 47: 505-11.
20. French GL, (2006) Bactericidal agents in the treatment of MRSA infections-the potential role of daptomycin. J. Antimicrob. Chemother. 58: 1107-17.
21. Amaral, L., M. Martins, M. Viveiros. 2007. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother 59: 1237-46.
22. Ohkuma S, Poole B, (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A 75: 3327-31.
23. Sibley LD, Weidner E, Krahenbuhl JL, (1985) Phagosome acidification blocked by intracellular Toxoplasma gondii. Nature 315: 416-9.
24. Vergne I, Chua J, Deretic V, (2003) Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+/calmodulin-PI3K hVPS34 cascade. J Exp Med 198: 653-9.
25. Vergne I, Chua J, Lee HH, Lucas M, Belisle J, Deretic V, (2005) Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 102: 4033-8.
26. Ganguly N, Siddiqui I, Sharma P, (2008) Role of M. tuberculosis RD-1 region encoded secretory proteins in protective response and virulence. Tuberculosis 88: 510-7.
27. Gomes MS, Paul S, Moreira AL, Appelberg R, Rabinovitch M, et al. (1999) Survival of Mycobacterium avium and Mycobacterium tuberculosis in acidified vacuoles of murine macrophages. Infect Immun 67: 3199-206.
28. Kim SY, Lee BS, Shin SJ, Kim HJ, Park JK, (2008) Differentially expressed genes in Mycobacterium tuberculosis H37Rv under mild acidic and hypoxic conditions. J Med Microbiol 57: 1473-80.
29. Fisher MA, Plikaytis BB, Shinnick TM, (2002) Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J Bacteriol 184: 4025-32.
30. Riska PF, Carleton S, (2002) Latent tuberculosis: models, mechanisms, and novel prospects for eradication. Semin Pediatr Infect Dis 13: 263-72.
31. Loebel RO, Shorr E, Richardson HB, (1933) The Influence of Adverse Conditions upon the Respiratory Metabolism and Growth of Human Tubercle Bacilli. J Bacteriol 26: 167-200.
32. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K, (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43: 717-31.
33. Cohen T, Becerra MC, Murray MB, (2004) Isoniazid resistance and the future of drug-resistant tuberculosis. Microb Drug Resist 10: 280-5.
34. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, et al. (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 198, 705-713.
35. Garbe TR, Hibler NS, Deretic V, (1999) Response to reactive nitrogen intermediates in Mycobacterium tuberculosis: induction of the 16-kilodalton alpha-crystallin homolog by exposure to nitric oxide donors. Infect Immun. 67: 460-5.
36. Hussain S, Malik M, Shi L, Gennaro ML, Drlica K (2009) In Vitro Model of Mycobacterial Growth Arrest Using Nitric Oxide with Limited Air. Antimicrob Agents Chemother 157-161.
37. Sinha I, Dick T, (2004) Role for malonyl coenzyme A:acyl carrier protein transacylase (MCAT) in the growth-inhibitory effect of the calmodulin antagonist trifluoperazine in Mycobacterium bovis BCG. J Antimicrob Chemother 53: 1072-5.
38. Yano T, Li LS, Weinstein E, The JS, Rubin H, (2006) Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J Biol Chem 281: 11456-63.
39. Chang YY, Ong YM, Chua KL, (2007) Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. Antimicrob Agents Chemother. 51: 623-30.
40. Redyy MV, Nadadhur G, Gangadharam PJ, (1996) In-vitro and intracellular antimycobacterial activity of trifluoperazine. J Antmucrob Chemother 37: 196-197.